Correlates of osteoprotegerin levels in women and men.
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Osteoprotegerin (OPG) is a potent antiresorptive molecule that binds the final effector for osteoclastogenesis, receptor activator of NF-kappaB ligand (RANK-L). OPG production is regulated by a number of cytokines and hormones, including sex steroids, but there are few data on age and gender effects on circulating serum OPG levels, as well as possible relationships between OPG levels and bone turnover markers or bone mineral density (BMD). Thus, we measured serum OPG levels in an age-stratified, random sample of men (n = 346 age range, 23-90 years) and women (n = 304; age range 21-93 years) and related them to sex steroid levels, bone turnover markers and BMD. Serum OPG levels increased with age in both men (R = 0.39, p < 0.001) and women (R = 0.18, p < 0.01). Premenopausal women had higher OPG levels than men under age 50 years (171 +/- 6 pg/ml vs 134 +/- 6 pg/ml, respectively, p < 0.001), whereas serum OPG levels were no different in postmenopausal women compared with men = 50 years (195 +/- 7 pg/ml vs 188 +/- 7 pg/ml, respectively, p = 0.179). OPG levels correlated inversely with serum bioavailable testosterone levels in men = 50 years (R = -0.27, p < 0.001), but no associations were present with either estrogen or testosterone levels in the women. In the men, there was a trend for OPG levels to be associated positively with bone resorption markers and inversely with BMD. Collectively, the gender difference in OPG levels suggests that sex steroids may regulate OPG production in vivo, as has been found in vitro. Moreover, OPG production may also rise with increases in bone turnover, probably as a homeostatic mechanism to limit bone loss. Further studies directly testing these hypotheses should provide additional insights into the potential role of OPG in bone loss related to aging and sex steroid deficiency.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Residual estrogen levels after the menopause correlate with bone density and fracture risk, yet the relationship of estrogen levels with serum OPG levels in postmenopausal women has been inconsistent across studies, with some supporting a weak relationship (375) and others no relationship (373, 379) or a negative correlation (381).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [373]
In the citing paper
“There is general agreement that OPG levels increase after the menopause (373, 379 -381) and with GnRH agonist therapy (382), both conditions of low estrogen levels.”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [373]
In the citing paper
“As with women, serum OPG levels increase with age in men (372,373,376,380,381,391,392).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [373]
In the citing paper
“the evidence is conflicting about an association between markers of bone turnover and circulating OPG because some studies report an association (154,372,375) or an association only among osteoporotic women (384), and others report no association (373,379).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [373]
In the citing paper
“Serum OPG levels have been found to be positively related to BMD (375, 379), negatively related to BMD (374, 383), or unrelated to BMD (372, 373) in postmenopausal women.”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [373]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.
Lacey, D. L., Timms, E., Tan, H.-L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81569-x · Cited by 5,439 · cited 5×
“Since it is at present unclear what proportion of circulating OPG is monomeric, dimeric or bound to RANK-L [10,24], it seems reasonable to use an assay that detects all forms of circulating OPG.”
BackgroundInfluentialSelf-citationOsteoprotegerin: a novel secreted protein involved in the regulation of bone density.
Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130 · cited 3×
“body and a rabbit polyclonal antibody for detection (Amgen, Thousand Oaks, CA) [3].”
BackgroundMethodSelf-citationYasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S.-I., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.7.3597 · Cited by 4,228 · cited 5×
“Since it is at present unclear what proportion of circulating OPG is monomeric, dimeric or bound to RANK-L [10,24], it seems reasonable to use an assay that detects all forms of circulating OPG.”
BackgroundInfluentialOsteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification.
Bucay, N., Sarosi, I., Dunstan, C. R., Morony, S., Tarpley, J., Capparelli, C., Scully, S., Tan, H. L., Xu, W., Lacey, D. L., et al. (1998) · Genes & Development · doi:10.1101/gad.12.9.1260 · Cited by 2,483 · cited 1×
“It is one of the most potent antiresorptive agents known, since transgenic mice overexpressing OPG have profound osteosclerosis and a virtual absence of osteoclasts [3] and, conversely, OPG knockout mice have marked osteopenia and increased numbers of osteoclasts [4,5].”
BackgroundSelf-citationHistory of the Rochester Epidemiology Project
Melton, L. J. (1996) · Mayo Clinic Proceedings · doi:10.4065/71.3.266 · Cited by 1,443 · cited 1×
“Subjects were recruited from age-stratified random samples of Rochester, Minnesota, men and women selected using the medical records linkage system of the Rochester Epidemiology Project [14].”
MethodHofbauer, L. C., Khosla, S., Dunstan, C. R., Lacey, D. L., Boyle, W. J., & Riggs, B. L. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.1.2 · Cited by 1,173 · cited 1×
“OPG production by osteoblastic cells is regulated by a number of cytokines and hormones, including sex steroids [6].”
BackgroundSelf-citationHofbauer, L. C., Khosla, S., Dunstan, C. R., Lacey, D. L., Spelsberg, T. C., & Riggs, B. L. (1999) · Endocrinology · doi:10.1210/endo.140.9.7131 · Cited by 692 · cited 2×
“Thus, several studies have found that estrogen (E) increases OPG production [7,8], whereas testosterone (T) tends to inhibit OPG mRNA and protein levels in osteoblastic cells [9].”
BackgroundSelf-citationBrowner, W. S., Lui, L.-Y., & Cummings, S. R. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.2.7192 · Cited by 506 · cited 2×
“[11] did not find any association between serum OPG levels and either BMD or fractures in a cohort of postmenopausal women.”
BackgroundYano, K., Tsuda, E., Washida, N., Kobayashi, F., Goto, M., Harada, A., Ikeda, K., Higashio, K., & Yamada, Y. (1999) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1999.14.4.518 · Cited by 363 · cited 9×
“[10] did note a positive association between serum OPG levels and markers of bone turnover and a negative association between OPG and BMD in postmenopausal women, although they did not report comparable data in men.”
BackgroundResultInfluentialDelmas, P. D., Stenner, D., Wahner, H. W., Mann, K. G., & Riggs, B. L. (1983) · Journal of Clinical Investigation · doi:10.1172/jci110882 · Cited by 353 · cited 1×
“Bone formation was assessed by serum osteocalcin, measured by RIA (interassay CV 56%) [18] as well as by serum bone-specific alkaline phosphatase (BSAP) measured by enzyme-linked immunosorbent assay [18] (ELISA; interassay CV 511%).”
MethodSelf-citation
Cited by
Pathogenesis of osteoporosis: concepts, conflicts, and prospects
Raisz, L. G. (2005) · Journal of Clinical Investigation · doi:10.1172/jci27071 · Cited by 1,779
Role of RANK ligand in mediating increased bone resorption in early postmenopausal women
Eghbali-Fatourechi, G., Khosla, S., Sanyal, A., Boyle, W. J., Lacey, D. L., & Riggs, B. L. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17215 · Cited by 825
“We believe that this may occur because estrogen deficiency and increased bone turnover affect OPG production in opposite directions with estrogen deficiency decreasing and increased bone turnover increasing OPG production (24, 47).”
BackgroundMethodInfluentialSelf-citationKearns, A. E., Khosla, S., & Kostenuik, P. J. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0014 · Cited by 824
Self-citationThe role of the immune system in the pathophysiology of osteoporosis
Clowes, J. A., Riggs, B. L., & Khosla, S. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00334.x · Cited by 359
“The relationship between OPG and BMD is equally mixed with negative (53), positive (58), and non-significant effects (54, 56, 57).”
BackgroundResultSelf-citationOsteoblast physiology in normal and pathological conditions
Neve, A., Corrado, A., & Cantatore, F. P. (2011) · Cell and Tissue Research · doi:10.1007/s00441-010-1086-1 · Cited by 331
“However, various studies analysing OPG and RANKL levels have given contrasting results (Grigorie et al. 2003; Khosla et al. 2002; Oh et al. 2005).”
ResultThe OPG/RANKL/RANK system in metabolic bone diseases.
Hofbauer, L. C., Kühne, C. A., & Viereck, V. (2004) · PubMed · Cited by 311
Osteoprotegerin as a Predictor of Coronary Artery Disease and Cardiovascular Mortality and Morbidity
Venuraju, S. M., Yerramasu, A., Corder, R., & Lahiri, A. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.03.013 · Cited by 237
“(45) howed that, in women, there is no significant association ith either estradiol or testosterone.”
BackgroundRogers, A., & Eastell, R. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0794 · Cited by 215
“This difference was not observed when postmenopausal women were compared with older men (44).”
BackgroundResultGoëb, V., & Anne-Priscille, T. (2010) · Clinical Interventions in Aging · doi:10.2147/cia.s10153 · Cited by 179
“In a large cohort of Chinese patients with either an extremely high hip BMD or an extremely low hip BMD, men with TC/CC genotypes of the polymorphism rs9594782 of the RANKL gene ( TNFRSF11 A ) had a significantly higher risk of extremely low hip BMD and lower whole-body BMD.”
InfluentialKhosla, S., Atkinson, E. J., Dunstan, C. R., & O’Fallon, W. M. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.4.8397 · Cited by 191
Self-citationAnand, D. V., Lahiri, A., Lim, E., Hopkins, D., & Corder, R. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.12.054 · Cited by 193
Serum levels of osteoprotegerin increase with age in a healthy adult population.
Kudlacek, S., Schneider, B., Woloszczuk, W., Pietschmann, P., & Willvonseder, R. (2003) · Bone · doi:10.1016/s8756-3282(03)00090-5 · Cited by 187
“A variety of local growth factors regulate the differentiation and the activity of the osteoblastic and osteoclastic lineage [1–3].”
BackgroundNitta, K., Akiba, T., Suzuki, K., Uchida, K., Watanabe, R.-I., Majima, K., Aoki, T., & Nihei, H. (2004) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(04)00937-0 · Cited by 174
Leeming, D. J., Alexandersen, P., Karsdal, M. A., Qvist, P., Schaller, S., & Tankó, L. B. (2006) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-006-0174-3 · Cited by 160
“OPG production is positively correlated with estrogen levels [ 60 ].”
BackgroundRasmussen, L. M., Tarnow, L., Hansen, T. K., Parving, H.-H., & Flyvbjerg, A. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02049 · Cited by 149
“In contrast to the present data, two previous papers have reported higher OPG levels in women than men in the same age group, as studied in the present study ( 25 , 26).”
Barreto, D. V., Barreto, F. D. C., Carvalho, A. B., Cuppari, L., Draibe, S. A., Dalboni, M. A., Moysés, R. M. A., Neves, K. R., Jorgetti, V., Miname, M. H., et al. (2008) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2008.06.024 · Cited by 144
Ouyang, P., Vaidya, D. M., Dobs, A. S., Golden, S. H., Szklo, M., Heckbert, S. R., Kopp, P. A., & Gapstur, S. M. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.08.037 · Cited by 136
Morabito, N., Gaudio, A., Lasco, A., Atteritano, M., Pizzoleo, M. A., Cincotta, M., La Rosa, M., Guarino, R., Meo, A., & Frisina, N. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040113 · Cited by 127
“Khosla et al.((41)) did not show any correlation between estrogen and OPG in women, whereas a negative correlation (always between OPG and E2) was present in men below 50 years of age.”
BackgroundSinnott, B. P., Syed, I., Sevrukov, A., & Barengolts, E. I. (2006) · Calcified Tissue International · doi:10.1007/s00223-005-0244-z · Cited by 144
“In the published reports, vascular calcification has been quantified by plain X-rays [ 35 , 24, 25, 50] and ultrasonography [7, 23, 27].”
BackgroundNovel Aspects on RANK Ligand and Osteoprotegerin in Osteoporosis and Vascular Disease
Sattler, A., Schoppet, M., Schaefer, J. R., & Hofbauer, L. C. (2003) · Calcified Tissue International · doi:10.1007/s00223-003-0011-y · Cited by 140
“markers and inversely with BMD, and were negatively correlated with bioavailable testosterone levels [19].”
BackgroundOsteoprotegerin plasma concentrations correlate with severity of peripheral artery disease
Ziegler, S., Kudlacek, S., Luger, A., & Minar, E. (2005) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2005.01.042 · Cited by 131
Local Production of Osteoprotegerin by Osteoblasts Suppresses Bone Resorption
Cawley, K. M., Bustamante-Gomez, N. C., Guha, A. G., MacLeod, R. S., Xiong, J., Gubrij, I., Liu, Y., Mulkey, R., Palmieri, M., Thostenson, J. D., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108052 · Cited by 114
“Circulating OPG levels do not consistently correlate with bone mass or the rate of bone remodeling in human studies (Khosla et al., 2002; Rogers and Eastell, 2005; Rogers et al., 2002; Sarink et al., 2019).”
Franck, H., Meurer, T., & Hofbauer, L. C. (2004) · PubMed · Cited by 109
Serum osteoprotegerin and its relationship with bone mineral density and markers of bone turnover.
Indridason, O. S., Franzson, L., & Sigurdsson, G. (2005) · Osteoporosis International · doi:10.1007/s00198-004-1699-x · Cited by 107
“In another study, a strong independent positive association between OPG and BMD was found in cardiac transplant patients [15]; however, several other studies have not demonstrated an association between OPG and BMD [8, 10, 12, 13, 14].”
BackgroundResultInfluentialVitamin K, circulating cytokines, and bone mineral density in older men and women
Shea, M. K., Dallal, G. E., Dawson-Hughes, B. F., Ordovás, J. M., O’Donnell, C. J., Gundberg, C. M., Peterson, J. W., & Booth, S. L. (2008) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/88.2.356 · Cited by 110
“Circulating osteoprotegerin increases with age (27, 28), and our cohort was older (mean age: 68 y) and within a narrower age range (60–81 y) compared with the community-based cohort, in which the mean age was 59 y (range: 35-89 y) (16).”
The role of osteoprotegerin in cardiovascular disease
Montagnana, M., Lippi, G., Danese, E., & Guidi, G. C. (2012) · Annals of Medicine · doi:10.3109/07853890.2012.727019 · Cited by 104
Mezquita-Raya, P., de la Higuera, M., García, D. F., Alonso, G., Ruiz-Requena, M. E., de Dios Luna, J., Escobar-Jiménez, F., & Muñoz-Torres, M. (2005) · Osteoporosis International · doi:10.1007/s00198-005-1844-1 · Cited by 98
“[11] found that serum OPG levels were not associated with estradiol in 304 women ranging in age from 21 to 93 years, and Seck et al.”
BackgroundInfluentialHirose, K., Tomiyama, H., Okazaki, R., Arai, T., Koji, Y., Zaydun, G., Hori, S., & Yamashina, A. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021511 · Cited by 100
Role of the RANK/RANKL/OPG and Wnt/β-Catenin Systems in CKD Bone and Cardiovascular Disorders
Workgroup, O. B. O. T. E. R. O. (., Carrillo-López, N., Martínez-Arias, L., Fernández-Villabrille, S., Ruiz-Torres, M. P., Dusso, A., Cannata-Andía, J. B., Naves-Díaz, M., & Panizo, S. (2021) · Calcified Tissue International · doi:10.1007/s00223-020-00803-2 · Cited by 91
Serum Osteoprotegerin in Adolescent Girls with Anorexia Nervosa
Misra, M., Soyka, L. A., Miller, K. K., Herzog, D. B., Grinspoon, S., de Chen, D., Neubauer, G., & Klibanski, A. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030088 · Cited by 92
“(32), we did find a positive correlation between free testosterone values and OPG in our healthy controls.”
BackgroundSex Differences in Proatherogenic Cytokine Levels
Bernardi, S., Toffoli, B., Tonon, F., Francica, M., Campagnolo, E., Ferretti, T., Comar, S., Giudici, F., Stenner, E., & Fabris, B. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21113861 · Cited by 93
“This finding is consistent with the literature, reporting that premenopausal women had higher OPG levels as compared to men under the age of 50 years [36], which should be ascribed to the stimulatory effect that estrogen has on OPG expression in osteoblast cells [37], where it inhibits bone resorption.”
ResultSkeletal turnover, bone mineral density, and fractures in male chronic abusers of alcohol
Santori, C., Ceccanti, M., Diacinti, D., Attilia, M. L., Toppo, L., D’Erasmo, E., Romagnoli, E., Mascia, M. L., Cipriani, C., Prastaro, A., et al. (2008) · Journal of Endocrinological Investigation · doi:10.1007/bf03346365 · Cited by 87
Riggs, B. L., Khosla, S., Atkinson, E. J., Dunstan, C. R., & Melton, L. J. (2003) · Osteoporosis International · doi:10.1007/s00198-003-1437-9 · Cited by 95
“It is also consistent with reports that serum OPG is increased in postmenopausal women [10, 15] and in postmenopausal osteoporotic women [15].”
ResultSelf-citationJ�rgensen, H. L., Kusk, P., Madsen, B., Fenger, M., & Lauritzen, J. B. (2004) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-003-0461-3 · Cited by 85
“sults reported by others [6,8,9], whereas BMD is known to decrease with age.”
BackgroundResultYilmaz, Y. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2012.05196.x · Cited by 82
Marini, H. R., Minutoli, L., Polito, F., Bitto, A., Altavilla, D., Atteritano, M., Gaudio, A., Mazzaferro, S., Frisina, A., Frisina, N., et al. (2008) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.080201 · Cited by 79
Gannagé‐Yared, M., Fares, F., Semaan, M., Khalife, S., & Jambart, S. (2006) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2006.02522.x · Cited by 76
Stern, A., Laughlin, G. A., Bergstrom, J., & Barrett-Connor, E. L. (2007) · European Journal of Endocrinology · doi:10.1530/eje-06-0753 · Cited by 81
“In vitro studies have shown that estrogen increases OPG, while testosterone and the non-aromatizable androgen 5a-dihydrotestosterone seemingly have the opposite effect ( 15 , 28, 29, 34, 35).”
BackgroundSignaling Axis in Osteoclast Biology and Therapeutic Targeting in the RANKL/RANK/OPG System
Tanaka, S. (2007) · American Journal of Nephrology · doi:10.1159/000106484 · Cited by 84
Min, S., Wang, C., Lu, W., Xu, Z., Shi, D., Chen, D., Teng, H., & Jiang, Q. Y. (2017) · Clinical Rheumatology · doi:10.1007/s10067-017-3690-x · Cited by 79
Oh, K. W., Rhee, E. J., Lee, W. Y., Kim, S. W., Baek, K. H., Kang, M. I., Yun, E. J., Park, C. Y., Ihm, S. H., Choi, M. G., et al. (2005) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2004.02179.x · Cited by 73
“…a positive correlation between serum OPG levels and total body, total hip and femoral neck BMD, although these correlations disappeared after adjusting for age and BMI and in a study by Khosla et al. (2002), mid-lateral spine BMD was inversely correlated with BMD in males under the age of 50.”
BackgroundResultMartini, G., Gennari, L., Merlotti, D., Salvadori, S., Franci, M. B., Campagna, S., Avanzati, A., De Paola, V., Valleggi, F., & Nuti, R. (2007) · Bone · doi:10.1016/j.bone.2006.08.003 · Cited by 72
“003 testosterone decreases while estrogen increases OPG levels [4–6].”
BackgroundHofbauer, L., Hicok, K., Chen, D., & Khosla, S. (2002) · European Journal of Endocrinology · doi:10.1530/eje.0.1470269 · Cited by 72
Self-citationAttia, E. A. S., Khafagy, A. H., Abdel-Raheem, S. M., Ahmed, S. F., & Saad, A. A. (2010) · International Journal of Dermatology · doi:10.1111/j.1365-4632.2010.04600.x · Cited by 74
Liu, J., Zhao, H., Ning, G., Zhao, Y. J., Chen, Y., Zhang, Z., Sun, L., Xu, M.-Y., & Chen, J. L. (2004) · Calcified Tissue International · doi:10.1007/s00223-004-0007-2 · Cited by 76
Szulc, P., Samelson, E. J., Kiel, D. P., & Delmas, P. D. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090531 · Cited by 67
Tauchmanovà, L., Colao, A. A. L., Lombardi, G., Rotoli, B., & Selleri, C. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2870 · Cited by 69
“Serum OPG (sOPG) was found to be increased in various conditions characterized by bone loss, including post-SCT status (21, 45, 46); this increase has been explained as a possible homeostatic mechanism limiting the more rapid bone loss (47); however, the exact skeletal and nonskeletal contributions to circulating OPG…”
BackgroundAshley, D. T., O'Sullivan, E. P., Davenport, C., Devlin, N. F. C., Crowley, R. K., McCaffrey, N., Moyna, N. M., Smith, D., & O’Gorman, D. J. (2010) · Metabolism · doi:10.1016/j.metabol.2010.10.001 · Cited by 70
“[27] Khosla S, Arrighi HM, Melton III LJ, Atkinson EJ, O'Fallon WM, Dunstan C, et al.”
BackgroundResultGonzález‐Álvaro, I., Ortiz, A. M., Tomero, E., Balsa, A., Orte, J., Laffón, A., & García‐Vicuña, R. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.071910 · Cited by 64
Fahrleitner-Pammer, A., Dobnig, H., Piswanger-Soelkner, C., Bonelli, C., Dimai, H.-P., Leb, G., & Obermayer-Pietsch, B. (2003) · Wiener Klinische Wochenschrift · doi:10.1007/bf03040334 · Cited by 62
“found an inverse relationship between OPG serum levels and bone mass in postmenopausal women [13], and recently published data showed similar findings in a cohort of healthy men [14].”
BackgroundResultOh, E. S., Rhee, E.-J., Oh, K. W., Lee, W. Y., Baek, K. H., Yoon, K. H., Kang, M. I., Yun, E. J., Park, C. Y., Choi, M. G., et al. (2005) · Metabolism · doi:10.1016/j.metabol.2004.08.005 · Cited by 61
Increased RANKL/OPG mRNA Ratio in Iliac Bone Biopsies From Women with Hip Fractures
Abdallah, B. M., Stilgren, L. S., Nissen, N., Kassem, M., Jørgensen, H. R. I., & Abrahamsen, B. (2005) · Calcified Tissue International · doi:10.1007/s00223-004-0074-4 · Cited by 60
“In addition, OPG levels have been reported to be negatively correlated with BMD in elderly men [39].”
BackgroundB Cell Production of Both OPG and RANKL is Significantly Increased in Aged Mice
N. Weitzmann, M., Li, Y., Terauchi, M., Vikulina, T., & Roser-Page, S. (2015) · The Open Bone Journal · doi:10.2174/1876525401406010008 · Cited by 53
“It has further been suggested that this rise in OPG may be a homeostatic mechanism to limit bone loss [14].”
BackgroundBrändström, H., Gerdhem, P., Stiger, F., Obrant, K. J., Melhus, H., Ljunggren, Ö., Kindmark, A., & Åkesson, K. (2003) · Calcified Tissue International · doi:10.1007/s00223-002-2136-9 · Cited by 54
“the above-mentioned study of women, serum OPG was not associated with bone mineral density or fracture [27], whereas an inverse relationship among bone density, bone resorption and serum OPG was suggested to be present in men [29, 30].”
Stilgren, L. S., Rettmer, E., Eriksen, E. F., Hegedűs, L. D., Beck‐Nielsen, H., & Abrahamsen, B. (2004) · Bone · doi:10.1016/j.bone.2004.03.012 · Cited by 55
“First, OPG is also influenced by other hormones, for example, estradiol, testosterone, and growth hormone [14,30–33].”
BackgroundBiglycan Deficiency Interferes With Ovariectomy-Induced Bone Loss
Nielsen, K. L., Allen, M. R., Bloomfield, S. A., Andersen, T. L., Chen, X., Poulsen, H. S., Young, M. F., & Heegaard, A. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.12.2152 · Cited by 52
Trofimov, S., Pantsulaia, I., Kobyliansky, E., & Livshits, G. (2004) · European Journal of Endocrinology · doi:10.1530/eje.0.1500305 · Cited by 51
“For example, Khosla’s team ( 11 ) did not detect in women any significant correlation between serum OPG levels and estradiol (ESTR) concentrations, while in men they tended to be inversely correlated with the bioavailable ESTR levels.”
InfluentialGranchi, D., Pellacani, A. U. E., Spina, M., Cenni, E., Savarino, L., Baldini, N., & Giunti, A. (2006) · Journal of Bone and Joint Surgery · doi:10.2106/00004623-200607000-00011 · Cited by 50
Buzi, F., Maccarinelli, G., Guaragni, B., Ruggeri, F., Radetti, G., Meini, A., Mazzolari, E., & Cocchi, D. (2003) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2004.01951.x · Cited by 52
Samelson, E. J., Broe, K. E., Demissie, S., Beck, T., Karasik, D., Kathiresan, S., & Kiel, D. P. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2492 · Cited by 49
“In contrast, no association between OPG and femoral neck bone density was found in 304 women in the Rochester Epidemiology Project (12) or 180 women in the European Vertebral Osteoporosis Study (31).”
BackgroundAbrahamsen, B., Hjelmborg, J., Kostenuik, P. J., Stilgren, L. S., Kyvik, K. O., Adamu, S., Brixen, K., & Langdahl, B. L. (2005) · Bone · doi:10.1016/j.bone.2004.12.015 · Cited by 49
Effect of aromatase inhibition on bone metabolism in elderly hypogonadal men
Leder, B. Z., & Finkelstein, J. S. (2005) · Osteoporosis International · doi:10.1007/s00198-005-1890-8 · Cited by 44
“flicting results [75,76].”
Grinspoon, S. K., Friedman, A. J., Miller, K. K., Lippman, J., Olson, W. H., & Warren, M. P. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030033 · Cited by 43
Kim, M.-S., Na, W., & Sohn, C. (2013) · Journal of Clinical Biochemistry and Nutrition · doi:10.3164/jcbn.13-25 · Cited by 40
Turner, R. T., Rickard, D. J., Iwaniec, U. T., & Spelsberg, T. C. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-373884-4.00057-4 · Cited by 41
Titanji, K., Vunnava, A., Foster, A., Sheth, A. N., Lennox, J. L., Knežević, A., Shenvi, N. V., Easley, K. A., Ofotokun, I., & Weitzmann, M. N. (2018) · AIDS · doi:10.1097/qad.0000000000001764 · Cited by 38
“Indeed, OPG production is reported to significantly increase with age in humans [27,28] and guidelines for the treatment and management of bone disease in HIV infection recommend the use of z-scores for interpretation of DXA scan data in individuals less than 50 years of age [29].”
BackgroundDoumouchtsis, K., Kostakis, A., Doumouchtsis, S. K., Grapsa, E., Passalidou, I., Tziamalis, M. P., Poulakou, M. V., Vlachos, I. S., & Perrea, D. N. (2008) · Hemodialysis International · doi:10.1111/j.1542-4758.2008.00249.x · Cited by 40
Traditional and Novel Bone Remodeling Markers in Premenopausal and Postmenopausal Women
Botella, S., Restituto, P., Monreal, I., Colina, I., Calleja, A., & Varo, N. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2264 · Cited by 41
RANKL inhibition for the management of patients with benign metabolic bone disorders
Anastasilakis, A. D., Toulis, K. A., Pοlyzos, S. A., & Terpos, E. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903048929 · Cited by 38
“Mean increase in hip BMD was 1.6 – 3.6% at 12 and 3.4 – 5.1% at 24 months.”
BackgroundInfluentialCalcium metabolism and vitamin D in the extreme longevity
Passeri, G., Vescovini, R., Sansoni, P., Galli, C., Franceschi, C., & Passeri, M. (2007) · Experimental Gerontology · doi:10.1016/j.exger.2007.06.013 · Cited by 49
“Studies on OPG/RANK/RANK-L network has provided new insights regarding bone remodelling as well as vascular diseases (Khosla et al.,2002; Schett et al.,2004, Hofbauer et al.,2004, Kiechel et al.,2006).”
BackgroundBiz, C., Khamisy‐Farah, R., Puce, L., Szarpak, Ł., Converti, M., Ceylan, H. İ., Crimì, A., Bragazzi, N. L., & Ruggieri, P. (2024) · Biomedicines · doi:10.3390/biomedicines12050974 · Cited by 40
LaCroix, A. Z., Jackson, R. D., Aragaki, A. K., Kooperberg, C. L., Cauley, J. A., Chen, Z., LeBoff, M. S., Duggan, D. J., & Wactawski‐Wende, J. (2013) · Bone · doi:10.1016/j.bone.2013.05.018 · Cited by 36
“Other tissues besides osteoblasts produce RANKL and OPG and thus, measurements of these biomarkers in the serum may reflect both skeletal and non-skeletal sources, as well as age-related differences in clearance [2].”
Duan, P., Yang, M., Wei, M., Liu, J., & Tu, P. (2017) · International Journal of Endocrinology · doi:10.1155/2017/8724869 · Cited by 37
“The increasing serum concentrations of OPG with aging could be explained by a compensatory mechanism to counteract the acceleration of bone resorption [44].”
BackgroundOh, K. W., Rhee, E., Lee, W., Kim, S. W., Oh, E. S., Baek, K. H., Kang, M. I., Choi, M. G., Yoo, H. J., & Park, S. W. (2004) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2004.02090.x · Cited by 36
“(Yano et al., 1999; Khosla et al., 2002).”
BackgroundRhee, E., Oh, K.-W., Lee, W., Kim, S.-Y., Oh, E.-S., Baek, K., Kang, M.-I., & Kim, S.-W. (2005) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2004.09.033 · Cited by 34
Circulating RANKL is inversely related to RANKL mRNA levels in bone in osteoarthritic males
Findlay, D. M., Chehade, M. J., Tsangari, H., Neale, S. D., Hay, S. J., Hopwood, B., Pannach, S., O’Loughlin, P. D., & Fazzalari, N. L. (2008) · Arthritis Research & Therapy · doi:10.1186/ar2348 · Cited by 39
“Significant correlations have been described for serum OPG with age in both men and women [33], although this is most easily observed in an extended age range from young adult to Table 2”
Monegal, A., Navasa, M., Peris, P., Alvarez, L., Pons, F., Rodés, J., & Guañabens, N. (2007) · Liver International · doi:10.1111/j.1478-3231.2007.01448.x · Cited by 31
“Moreover, it should be noted that in healthy and in osteoporotic postmenopausal populations the relationship between OPG serum levels and markers of bone turnover is somewhat inconclusive, showing indistinctly positive and negative associations (15, 16).”
BackgroundFortner, R. T., Sarink, D., Schöck, H., Johnson, T., Tjønneland, A. M., Olsen, A., Overvad, K., Affret, A., His, M., Boutron‐Ruault, M., et al. (2017) · BMC Medicine · doi:10.1186/s12916-017-0786-8 · Cited by 30
“As in other recent studies [22, 61], we observed no systematic variation of serum OPG concentration with phase of menstrual cycle or with menopausal status (after adjustment for age at blood collection) [62], and a gradual rise of OPG levels with increasing age [58, 62, 63].”
Jørgensen, L., Vik, A., Emaus, N., Brox, J. H., HANSEN, J. ‐., Mathiesen, E. B., & Vestergaard, P. (2009) · Osteoporosis International · doi:10.1007/s00198-009-1035-6 · Cited by 30
“The major part of the previous studies is cross sectional and has examined the relationship between OPG and spine BMD [4-12, 14, 15, 18, 19, 21, 28].”
BackgroundResultInfluentialIntracellular and surface RANKL are differentially regulated in patients with ankylosing spondylitis
Stupphann, D., Rauner, M., Krenbek, D., Patsch, J., Pirker, T., Muschitz, C., Resch, H., & Pietschmann, P. (2008) · Rheumatology International · doi:10.1007/s00296-008-0567-y · Cited by 30
Stilgren, L. S., Heged�s, L., Beck‐Nielsen, H., & Abrahamsen, B. (2003) · Calcified Tissue International · doi:10.1007/s00223-002-2100-8 · Cited by 29
Lewis, J. R., Lim, W. H., Zhu, K., Wong, G., Dhaliwal, S. S., Lim, E. M., Ueland, T., Bollerslev, J., & Prince, R. L. (2014) · American Journal of Nephrology · doi:10.1159/000357787 · Cited by 27
Pulsatelli, L., Dolzani, P., Silvestri, T., Caraceni, P., Facchini, A., Ravaglia, G., Salvarani, C., Melicòni, R., & Mariani, E. (2004) · Biogerontology · doi:10.1023/b:bgen.0000025075.04136.ec · Cited by 28
“Apparently different results were reported by Khosla et al. (2002), although those investigators stated that a difference in circulating concentrations of OPG was found between men and premenopausal women, but not in men aged over 50 years compared to postmenopausal women.”
ResultInfluentialSzulc, P., Hawa, G., Boutroy, S., Vilayphiou, N., Schoppet, M., Chapurlat, R. D., & Hofbauer, L. C. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2617 · Cited by 25
Doumouchtsis, K., Kostakis, A., Doumouchtsis, S. K., Tziamalis, M. P., Tsigris, C., Kostaki, M., & Perrea, D. N. (2007) · Journal of Endocrinological Investigation · doi:10.1007/bf03350814 · Cited by 25
Osteoprotegerin and bone mineral density in hemodialysis patients
Nakashima, A., Yorioka, N., Doi, S., Takasugi, N., Shigemoto, K., & Kohno, N. (2006) · Osteoporosis International · doi:10.1007/s00198-005-0047-0 · Cited by 25
“[6] found that the serum osteoprotegerin level showed a positive correlation with markers of bone metabolism, while there was a negative correlation with bone mineral density (BMD).”
BackgroundDovio, A., Allasino, B., Palmas, E., Ventura, M., Pia, A. R., Saba, L., Aroasio, E., Terzolo, M., & Angeli, A. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2283 · Cited by 28
Malyszko, J., Małyszko, J., Wołczyński, S., & Myśliwiec, M. (2003) · Transplantation Proceedings · doi:10.1016/s0041-1345(03)00755-3 · Cited by 24
GH replacement therapy increases plasma osteoprotegerin levels in GH-deficient adults
Lanzi, R., Losa, M., Villa, I., Gatti, E., Sirtori, M., Fiume, C. D., & Rubinacci, A. (2003) · European Journal of Endocrinology · doi:10.1530/eje.0.1480185 · Cited by 23
“This mechanism, which becomes operative in elderly men as well as in postmenopausal women (43, 44 ) with enhanced bone remodeling, is regulated by a concert of regulatory factors, besides GH, that participate in bone mass homeostasis.”
BackgroundSyversen, S. W., Landewé, R., van der Heijde, D. M. F. M., Bathon, J. M., Boers, M., Bykerk, V. P., FitzGerald, O., Gladman, D. D., Garnero, P., Geusens, P., et al. (2009) · The Journal of Rheumatology · doi:10.3899/jrheum.090262 · Cited by 22
Kim, C. S., Bae, E. H., Kwon, S., Han, S. H., Choi, K. H., Lee, J., Chae, D., Oh, K., Ahn, C., Kim, S. W., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0166792 · Cited by 23
Circulating osteoprotegerin is associated with chronic kidney disease in hypertensive patients
Bernardi, S., Toffoli, B., Bossi, F., Candido, R., Stenner, E., Carretta, R., Barbone, F., & Fabris, B. (2017) · BMC Nephrology · doi:10.1186/s12882-017-0625-3 · Cited by 23
“In the group of patients with CKD there were more women, however, this should not have affected our final data because it has been demonstrated that serum OPG levels are not different in postmenopausal women compared to men [56], and our multivariate analyses were adjusted for age and sex.”
ResultPolymorphisms at the Osteoprotegerin and Interleukin-6 Genes in Relation to First-Ever Stroke
Strand, M., Söderström, I., Wiklund, P.-G., Hallmans, G., Weinehall, L., Söderberg, S., & Olsson, T. (2007) · Cerebrovascular Diseases · doi:10.1159/000108431 · Cited by 21
“This may be reflected by the fact that circulating OPG levels increase with age [”
BackgroundAli, Z., Ellington, A. A., Mosley, T. H., & Kullo, I. J. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.03.032 · Cited by 22
Miyata, T., Minami, M., Kataoka, H., Hayashi, K., Ikedo, T., Yang, T., Yamamoto, Y., Yokode, M., & Miyamoto, S. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.015731 · Cited by 22
“51 Estrogen, as a well-known protective factor of IA formation and rupture in humans, can also stimulate osteoprotegerin production.”
Angelopoulos, N., Goula, A., Katounda, E., Rombopoulos, G., Kaltzidou, V., Kaltsas, D., Malaktari, S., Athanasiou, V., & Tolis, G. (2006) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-006-0728-6 · Cited by 21
“Such sex and age differences in the OPG/RANKL system have been proved in the general population [14,28].”
BackgroundHalapas, A., Zacharoulis, A., Theocharis, S. E., Karavidas, A. I., Korres, D. S., Papadopoulos, K., Katopodis, H., Stavropoulou, A., Lembessis, P., Xiromeritis, C., et al. (2008) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2008.091 · Cited by 21
“As serum measurements of OPG and RANKL are affected by gender (13, 14), we only enrolled patients of male gender in our study.”
BackgroundSerum levels of cathepsin K decrease with age in both women and men
Kerschan‐Schindl, K., Hawa, G., Kudlacek, S., Woloszczuk, W., & Pietschmann, P. (2005) · Experimental Gerontology · doi:10.1016/j.exger.2005.04.001 · Cited by 33
Ren, Y., Liu, Y., Jiang, K., Li, L., Jiao, N., Zhu, Z., Zhang, K., Jiang, S., Yang, W., & Li, Y. (2023) · Animals · doi:10.3390/ani13061042 · Cited by 20
“stimulate and exacerbate the compensatory proliferation of osteoblasts to inhibit abnormal bone resorption [41,42].”
BackgroundMashavi, M., Menaged, M., & Shargorodsky, M. (2017) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000000914 · Cited by 20
“not find any correlation between OPG levels and parameters of BMD.(6,18) However, a positive and negative association between OPG and BMD parameters has been reported.”
Background
Metadata
- Authors
- Khosla, S., Arrighi, H. M., Melton, III, Atkinson, E. J., O'Fallon, W. M., Dunstan, C., & Riggs, B. L.
- Affiliations
- Mayo Clinic (US)
- Amgen (United States) (US)
- Venue
- Osteoporosis International
- Published
- 2002-05-01
- Volume
- 13
- Issue
- 5
- Pages
- 394-399
- ISSN
- 0937-941X (ISSN-L)
- 1433-2965
- OpenAlex
- W2034959911
- Cited by
- 205
- References
- 19
- Citations by year
- 2026: 5 · 2025: 2 · 2024: 6 · 2023: 3 · 2022: 3 · 2021: 5 · 2020: 3 · 2019: 5 · 2018: 3 · 2017: 6 · 2016: 5 · 2015: 4 · 2014: 6 · 2013: 9 · 2012: 10
- FWCI
- 6.56
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Osteoporosis International (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (AR 27065, R01AR027065)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- Keywords
- osteoprotegerin, sex steroids, testosterone, estrogen, bone turnover markers, bone mineral density, bone resorption, menopause, aging, sex differences, RANK ligand, bone loss, bone homeostasis
- MeSH terms
- Adult, Aged, Aged, 80 and over, Aging, Enzyme-Linked Immunosorbent Assay, Estradiol, Female, Glycoproteins, Humans, Male, Middle Aged, Sex Characteristics, Testosterone, Bone Remodeling, Premenopause, Postmenopause, Receptors, Tumor Necrosis Factor, Receptors, Cytoplasmic and Nuclear, Statistics, Nonparametric, Osteoprotegerin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.